- Home
- MLSS vs TCRX Comparison
MLSS vs TCRX Comparison
Compare MLSS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLSS
- TCRX
- Stock Information
- Founded
- MLSS 1989
- TCRX 2018
- Country
- MLSS United States
- TCRX United States
- Employees
- MLSS N/A
- TCRX N/A
- Industry
- MLSS Industrial Specialties
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLSS Health Care
- TCRX Health Care
- Exchange
- MLSS Nasdaq
- TCRX Nasdaq
- Market Cap
- MLSS 74.9M
- TCRX 82.1M
- IPO Year
- MLSS 1995
- TCRX 2021
- Fundamental
- Price
- MLSS $0.67
- TCRX $1.51
- Analyst Decision
- MLSS Buy
- TCRX Strong Buy
- Analyst Count
- MLSS 1
- TCRX 6
- Target Price
- MLSS $1.25
- TCRX $9.50
- AVG Volume (30 Days)
- MLSS 101.2K
- TCRX 604.8K
- Earning Date
- MLSS 08-13-2025
- TCRX 08-11-2025
- Dividend Yield
- MLSS N/A
- TCRX N/A
- EPS Growth
- MLSS N/A
- TCRX N/A
- EPS
- MLSS N/A
- TCRX N/A
- Revenue
- MLSS $8,613,503.00
- TCRX $4,421,000.00
- Revenue This Year
- MLSS $29.14
- TCRX $159.20
- Revenue Next Year
- MLSS $20.19
- TCRX N/A
- P/E Ratio
- MLSS N/A
- TCRX N/A
- Revenue Growth
- MLSS N/A
- TCRX N/A
- 52 Week Low
- MLSS $0.57
- TCRX $1.02
- 52 Week High
- MLSS $1.39
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- MLSS 28.44
- TCRX 50.74
- Support Level
- MLSS $0.61
- TCRX $1.39
- Resistance Level
- MLSS $0.81
- TCRX $1.73
- Average True Range (ATR)
- MLSS 0.06
- TCRX 0.13
- MACD
- MLSS -0.02
- TCRX -0.01
- Stochastic Oscillator
- MLSS 28.57
- TCRX 38.24
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.